Objectives

Osimertinib is a third-generation, irreversible tyrosine kinase inhibitor of the epidermal growth factor receptor (EGFR-TKI) showing longer progression free survival and overall survival than other EGFR-TKI with an improvement in tolerability.

Materials and Methods

We report about an advanced lung adenocarcinoma patient with severe aplastic anemia during first line osimertinib.

Results and Conclusion

Severe hematologic toxicity is extremely rare but possible with osimertinib and clinicians should be careful about changes in blood cell count during the use of it.

中文翻译：

---

一线奥美替尼期间晚期肺腺癌患者再生障碍性贫血：病例报告和文献复习。

目标

Osimertinib是表皮生长因子受体（EGFR-TKI）的第三代不可逆酪氨酸激酶抑制剂，与其他EGFR-TKI相比，其无进展生存期和总生存期更长，并且耐受性得到改善。

材料和方法

我们报道了一线奥美替尼期间患有严重再生障碍性贫血的晚期肺腺癌患者。

结果与结论

严重的血液学毒性极为罕见，但使用奥西替尼可能发生，临床医生在使用期间应注意血细胞计数的变化。